Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 13/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 10/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.65 |
| ▸ | LMNA | P02545 | 4/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.65 |
| ▸ | HTT | P42858 | 2/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 8/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.51 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.51 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5974454 | 0.95 | FDPS (0.77) | FDPSALDH1A1TSHRMAPTSMN1; SMN2 | |
| SCHEMBL1515797 | 0.92 | FDPS (0.78) | FDPSALDH1A1TSHRMAPTSMN1; SMN2 | |
| SCHEMBL3924101 | 0.92 | ALDH1A1 (0.63) | FDPSALDH1A1TSHRMAPTSMN1; SMN2 | |
| SCHEMBL13590011 | 0.90 | FDPS (0.75) | FDPSALDH1A1TSHRMAPTSMN1; SMN2 | |
| SCHEMBL5974612 | 0.90 | FDPS (0.75) | FDPSALDH1A1TSHRMAPTSMN1; SMN2 | |
| SCHEMBL7661907 | 0.90 | FDPS (0.86) | FDPSALDH1A1TSHRMAPTSMN1; SMN2 | |
| SCHEMBL3924488 | 0.87 | FDPS (0.71) | FDPSALDH1A1TSHRMAPTSMN1; SMN2 | |
| SCHEMBL1748837 | 0.87 | FDPS (0.71) | FDPSALDH1A1TSHRMAPTSMN1; SMN2 | |
| SCHEMBL30462849 | 0.87 | FDPS (0.71) | FDPSALDH1A1TSHRMAPTSMN1; SMN2 | |
| SCHEMBL8905918 | 0.86 | FDPS (0.69) | FDPSALDH1A1TSHRMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011148392-A1 | PROCESS FOR THE PREPARATION OF (2S,4S,5S,7S)-N-(2-CARBAMYL-2- METHYLPROPYL)-5-AMINO-4-HYDROXY-2,7-DIISOPROPYL-8-[4-METHOXY-3-(3- METHOXYPROPOXY)PHENYL]-OCTANAMIDE HEMIFUMARATE AND ITS INTERMEDIATES THEREOF | MSN LABORATORIES LIMITED (IN) | 2011-12-01 | — | — | WO | claimed |
| CN-109400553-B | Preparation method of aliskiren intermediate | 常州红太阳药业有限公司 | 2022-03-18 | — | — | CN | disclosed |
| US-20220017536-A1 | Crystal Form of Hepatitis B Surface Antigen Inhibitor | FUJIAN AKEYLINK BIOTECHNOLOGY CO., LTD. (CN) | 2022-01-20 | — | — | US | disclosed |
| US-20200197409-A1 | HEPATITIS B VIRUS SURFACE ANTIGEN INHIBITOR | FUJIAN COSUNTER PHARMACEUTICAL CO., LTD. (CN) | 2020-06-25 | — | — | US | disclosed |
| WO-2018154466-A1 | DIHYDROQUINOLIZINONES AS ANTIVIRALS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-08-30 | — | — | WO | disclosed |
| EP-2168952-B1 | MORPHOLINE DERIVATIVES AS RENIN INHIBITORS | MITSUBISHI TANABE PHARMA CORP (JP) | 2017-02-15 | — | — | EP | disclosed |
| US-9346745-B2 | Process for producing Aliskiren | CHEMO IBERICA, S.A. (ES) | 2016-05-24 | — | — | US | disclosed |
| US-8975252-B2 | Morpholine derivative | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2015-03-10 | — | — | US | disclosed |
| US-20130252288-A1 | ENANTIOSELECTIVE REDUCTION | DSM IP ASSETS B.V. (NL) | 2013-09-26 | — | — | US | disclosed |
| EP-2576500-A2 | PROCESS FOR PRODUCING ALISKIREN | Chemo Iberica, S.A. (ES) | 2013-04-10 | — | — | EP | disclosed |
| US-6683206-B2 | STEREOSELECTIVE ADDITION TO BENZALDEHYDES; REGIOSELECTIVE ELIMINATION TO FORM 3-R-2-R3-PROPENIC ACID ESTERS; HYDROLYSIS; HYDROGENATION USING RUTHENIUM, RHODIUM OR IRIDIUM CATALYST | SPEEDEL PHARMA AG (CH) | 2004-01-27 | — | — | US | disclosed |
| US-20030139625-A1 | Preparation of (r -2-alkyl-3-phenylpropionic acids | SPEEDEL PHARMA AG (CH) | 2003-07-24 | — | — | US | disclosed |
| EP-1296927-A1 | PREPARATION OF (R)-2-ALKYL-3-PHENYLPROPIONIC ACIDS | Speedel Pharma AG (CH) | 2003-04-02 | — | — | EP | disclosed |
| EP-1296912-A1 | PROCESS FOR THE PREPARATION OF (R)-2-ALKYL-3-PHENYL-1-PROPANOLS | Speedel Pharma AG (CH) | 2003-04-02 | — | — | EP | disclosed |
| EP-1200390-A1 | PRODUCTION OF N-SUBSTITUTED 2,7-DIALKYL-4-HYDROXY-5-AMINO-8-ARYL-OCTANOYLAMIDES | Speedel Pharma AG (CH) | 2002-05-02 | — | — | EP | disclosed |
| WO-2002002500-A1 | PREPARATION OF (R)-2-ALKYL-3-PHENYLPROPIONIC ACIDS | SPEEDEL PHARMA AG (CH) | 2002-01-10 | — | — | WO | disclosed |
| WO-2002002487-A1 | PROCESS FOR THE PREPARATION OF (R)-2-ALKYL-3-PHENYL-1-PROPANOLS | SPEEDEL PHARMA AG (CH) | 2002-01-10 | — | — | WO | disclosed |
| WO-2001009083-A1 | PRODUCTION OF N-SUBSTITUTED 2,7-DIALKYL-4-HYDROXY-5-AMINO-8-ARYL-OCTANOYLAMIDES | SPEEDEL PHARMA AG (CH) | 2001-02-08 | — | — | WO | disclosed |
| US-5659065-A | CHEMICAL INTERMEDIATES FOR MEDICINAL ACTIVE AGENTS | NOVARTIS CORPORATION (US) | 1997-08-19 | — | — | US | disclosed |
| EP-0678500-A1 | Alpha-amino alkanoic acids and reduction products as intermediates in the preparation of renin inhibitors | CIBA-GEIGY AG (CH) | 1995-10-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139625-A1 | Preparation of (r -2-alkyl-3-phenylpropionic acids | PCCA, APEH, ALDH1A1 | FDPS 1515/4885ALDH1A1 3/4885TSHR 1798/4885 |
| US-20220017536-A1 | Crystal Form of Hepatitis B Surface Antigen Inhibitor | HAVCR2, HLA-B, CD74 | FDPS 826/4885ALDH1A1 1426/4885TSHR 3617/4885 |
| US-20200197409-A1 | HEPATITIS B VIRUS SURFACE ANTIGEN INHIBITOR | HAVCR2, CD74, HLA-B | FDPS 3777/4885ALDH1A1 1143/4885TSHR 2807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.